Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson’s Disease at the Prodromal Stage
Authors:
- Elena A. KatuninaEKElena A. Katunina
- Victor BlokhinVBVictor Blokhin
- Marina R. NodelMNMarina R. Nodel
- Ekaterina N. PavlovaEPEkaterina N. Pavlova
- Alexander L. KalinkinAKAlexander L. Kalinkin
- Valerian G. KucheryanuVKValerian G. Kucheryanu
- Leyla AlekperovaLALeyla Alekperova
- Marianna V. SelikhovaMSMarianna V. Selikhova
- Mikhail Yu. MartynovMMMikhail Yu. Martynov
- Michael V. UgrumovMichael V. Ugrumov
Open Access
- 17 January 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (3) , 1842
Abstract
Parkinson’s disease (PD) is diagnosed many years after its onset, under a significant degradation of the nigrostriatal dopaminergic system, responsible for the regulation of motor function. This explains the low effectiveness of the treatment of patients. Therefore, one of the highest priorities in neurology is the development of the early (preclinical) diagnosis of PD. The aim of this study was to search for changes in the blood of patients at risk of developing PD, which are considered potential diagnostic biomarkers. Out of 1835 patients, 26 patients were included in the risk group and 20 patients in the control group. The primary criteria for inclusion in a risk group were the impairment of sleep behavior disorder and sense of smell, and the secondary criteria were neurological and mental disorders. In patients at risk and in controls, the composition of plasma and the expression of genes of interest in lymphocytes were assessed by 27 indicators. The main changes that we found in plasma include a decrease in the concentrations of l-3,4-dihydroxyphenylalanine (L-DOPA) and urates, as well as the expressions of some types of microRNA, and an increase in the total oxidative status. In turn, in the lymphocytes of patients at risk, an increase in the expression of the DA D3 receptor gene and the lymphocyte activation gene 3 (LAG3), as well as a decrease in the expression of the Protein deglycase DJ-1 gene (PARK7), were observed. The blood changes we found in patients at risk are considered candidates for diagnostic biomarkers at the prodromal stage of PD.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (075-15-2020-795, 13.1902.21.0027, RF-190220X0027)
This publication has 124 references indexed in Scilit:
- Parkinson Disease and Sleep: Sleep–Wake Changes in the Premotor Stage of Parkinson Disease; Impaired Olfaction and Other Prodromal FeaturesCurrent Neurology and Neuroscience Reports, 2013
- Comparison of REM sleep behaviour disorder variables between patients with progressive supranuclear palsy and those with Parkinson’s diseaseParkinsonism & Related Disorders, 2012
- Biochemical premotor biomarkers for Parkinson's diseaseMovement Disorders, 2012
- Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET studyNeuroImage, 2011
- REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a centuryNeurology, 2010
- The immunoregulatory role of dopamine: An updateBrain, Behavior, and Immunity, 2010
- CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.Acta Neurologica Scandinavica, 2009
- Action of biologically-relevant oxidizing species upon uric acid. Identification of uric acid oxidation productsChemico-Biological Interactions, 1990
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.Proceedings of the National Academy of Sciences, 1981